Sinonasal Neuroendocrine CarcinomaPhase 1NCT06479811
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
A Phase 1 study testing [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET and 68Ga-DOTATATE in people with Sinonasal Neuroendocrine Carcinoma and Nasopharyngeal Carcinoma, run by National Cancer Institute (NCI) at 1 site in United States.
Trial summary
Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Read more about this study
- Who is it for?
- Ages 18 to 120 years
- Conditions the study is for
- Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma
- What is being tested?
- [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET and 68Ga-DOTATATE
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Aug 2025to 1 Jan 2032
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants must have histopathologically confirmed gastrointestinal neuroendocrine tumors (GI NET), pheochromocytoma/paraganglioma (PPGL), small cell lung cancers (SCLC), kidney cancers (KC), or Head \& Neck cancers (nasopharyngeal carcinoma [NPC], olfactory neuroblastoma [ONB], sinonasal neuroendocrine carcinoma [SNEC]) that are metastatic or inoperable per Standard of Care. Note: for KC, all histopathologies of kidney cancers are eligible as long as it is a primary renal neoplasm.
- Required prior therapies:
- GI NET, PPGL, H\&N: no specific prior therapy is needed.
- SCLC: At least one prior line of standard of care systemic treatment such as chemotherapy and/or immunotherapy.
- KC: Renal cell carcinoma (RCC) participants should have received at least one line of prior therapy in the metastatic setting and should have received at least one Programmed cell death protein 1 (PD1) / Programmed death-ligand 1 (PDL1)-targeted immune checkpoint inhibitor as well as one agent targeting the VEGF pathway. Participants with fumarate hydratase (FH) deficient RCC should have received at least one prior line of systemic therapy (such as bevacizumab plus erlotinib). No prior therapy is needed for participants with other histologic subtypes.
- Have NOT received prior systemic radioligand therapy for definitive therapeutic purposes. Prior external beam radiation therapy is allowed.
Show all 33Show fewer
- History of disease progression by imaging (e.g., RECIST 1.1) or clinically (defined as increase in severity or frequency of symptoms related to disease) within the past 36 months prior to the first dose of [203Pb]VMT-Alpha-NET.
- Evidence of somatostatin receptors (SSTR) expression on at least 50% of the radiographically identifiable (i.e., visible on an anatomic scan such as CT or magnetic resonance imaging [MRI]) tumor, as indicated by a positive (uptake qualitatively identifiable as above the local background) on SSTR PET scan.
- Age >= 18 years.
- ECOG performance status <=1.
- Participants must have adequate organ and marrow function as defined below:
- Leukocytes: 3,000/microliter
- Absolute Neutrophil Count: 1,500/microliter
- Platelets 100,000/microliter
- Hemoglobin >= 9.0 g/dL
- Total bilirubin: within normal institutional limits. Note: <= 5 X institutional upper limit of normal (ULN) if bilirubin elevation is due to a benign process such as Gilbert syndrome
- AST: <= 2.5 X institutional ULN
- ALT: <= 2.5 X institutional ULN
- Creatinine: within normal institutional limits
- OR
- Calculated creatinine clearance (glomerular filtration rate (eGFR): >= 60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal
- Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression at screening.
- Participants with new or progressive brain metastases or leptomeningeal disease are eligible as long as the participant is asymptomatic and not requiring medication for symptom control from the brain lesions at screening.
- Participants seropositive for human immunodeficiency virus (HIV) must:
- be on effective anti-retroviral therapy; and
- have an undetectable viral load at screening.
- Participants seropositive for hepatitis B virus (HBV), must have HBV viral load undetectable at screening.
- Participants seropositive for hepatitis C virus (HCV) must:
- received curative treatment; and
- have an undetectable HCV viral load at screening.
- Individuals of child-bearing potential (IOCBP) and individuals who can father children must agree to use an effective method of contraception (barrier, hormonal, intrauterine device [IUD], surgical sterilization, abstinence) at study entry and at least 6 months after the last dose of the study agent(s).
- Nursing participants must be willing to discontinue nursing from study treatment initiation through 6 months after the last dose of the study agents.
- The ability of the participant to understand and the willingness to sign a written informed consent document.
Who cannot join
- Any investigational agents should be stopped at least 28 days prior to the first dose of [203Pb]VMT-Alpha-NET.
- Systemic therapy should be stopped at least 28 days prior to the first dose of [203Pb]VMT-Alpha-NET (participants with prior systemic therapies for their malignancy only, except participants with SCLC).
- Systemic therapy should be stopped at least 14 days prior to the first dose of [203Pb]VMT-Alpha-NET (participants with SCLC only).
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to VMT-Alpha-NET.
- Positive Beta human chorionic gonadotropin (Beta-HCG) serum or urine pregnancy test performed in IOCBP at screening.
- QTc > 450 ms on electrocardiogram (EKG) at screening. Note: Framingham correction for QTc will be used.
- History of or detection at screening of active/untreated secondary malignancy except nonmelanoma skin cancer and carcinoma in situ of the uterine cervix.
- Uncontrolled intercurrent illness, factors, evaluated by medical history and physical exam which would potentially increase in the risk of the participant.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
National Cancer Institute Referral Office, 888-624-1937, ncimo_referrals@mail.nih.gov
About this study
Official title: Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Background:
Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Researchers want to know if drug treatments that target SSTRs can help shrink these types of tumors.
Read more
Objective:
To test a study drug ([212Pb]VMT-Alpha-NET) in people with tumors that have SSTRs.
Eligibility:
People aged 18 years and older with tumors of the lung, kidneys, head and neck, digestive tract, or adrenal glands that have SSTRs. Their tumors must have spread to other organs and cannot be removed with surgery.
Design:
Participants will be screened. They will have a physical exam with blood and urine tests. They will have imaging scans and a test of their heart function. A sample of tumor tissue may be collected if one is not already available.
[212Pb]VMT-Alpha-NET is given through a tube attached to a needle inserted into a vein. The drug will be given on the first day of four 8-week cycles. Participants will stay in the hospital for a few nights after each dose. They will have blood tests once a week during each cycle.
Some participants will also get imaging with a related study drug ([203Pb]VMT-Alpha-NET). They will receive this drug within 30 days before each cycle. At 1, 4, 24, and 48 hours after each [203Pb]VMT-Alpha-NET infusion and 4 hours after each [212Pb]VMT-Alpha-NET infusion, they will have optional whole body scans. These scans will show where the study drug went in their body. Following treatment, participants will be invited to the NIH Clinical Center 8 weeks after the last study drug administration for an end of treatment (EOT) visit. After EOT, visits will continue every 12 weeks for years 1-3 and every 6 months for years 4-6 or until disease progression. Beyond 6 years (or disease progression), participants will be contacted yearly to assess health status for 10 years after EOT.
Read the detailed description
Background:
- Somatostatin receptors (SSTR) have been shown to be over-expressed in a number of human tumors, including gastrointestinal (GI) neuroendocrine tumors (NET), pheochromocytoma/paragangliomas (PPGL), small cell lung cancers (SCLC), kidney cancers (KC), and some head and neck (H\&N) cancers.
- Targeted radioligand therapy (TRT) is a class of cancer therapeutic agents formed by attaching a radioactive isotope to a ligand that can target specific surface receptors such as SSTR on a tumor cell membrane. Efficacy is typically determined by the radiation dose deposited onto a tumor, which is determined by the radioactive isotope being used as well as the binding characteristics of the ligand-receptor/transporter pair.
- Alpha emitters such as 212Pb emit alpha particles that are more damaging to tumor cells than beta emitters such as 177Lu. Therefore, TRT agents using alpha emitters are considered to be more potent than beta-emitting TRTs.
- VMT-Alpha-NET is a peptide that binds to SSTR, which when attached to 212Pb becomes an alpha particle-emitting TRT that can be used to treat tumors that have SSTR surface expression.
- [203Pb]VMT-Alpha-NET is the chemically identical imaging surrogate for [212Pb]VMT-Alpha-NET and has the same mechanism of action via binding to SSTR2. The nuclide 203Pb contained in [203Pb]VMT-Alpha-NET emits gamma radiation suitable for single-photon emission computerized tomography (SPECT) imaging. These images can be used to assess drug product biodistribution throughout the body.
Objective:
-To determine the maximum tolerated dose (MTD) of [212Pb]VMT-Alpha-NET (dose escalation cohort) and assess the safety of [212Pb]VMT-Alpha-NET at the MTD (dose expansions cohorts).
Eligibility:
- Age >= 18 years.
- Histopathologically confirmed GI NET, PPGL, SCLC, KC, or H\&N (nasopharyngeal carcinoma [NPC], olfactory neuroblastoma [ONB], sinonasal neuroendocrine carcinoma [SNEC]) cancers that are metastatic or inoperable.
- No prior systemic radioligand therapy.
- Eastern Cooperative Oncology Group (ECOG) Performance Status <= 1.
Design:
- This is an open-label, single-arm, single-center, phase I study evaluating the safety, preliminary efficacy, and pharmacokinetic properties of [212Pb]VMT-Alpha-NET in GI NET, PPGL, SCLC, KC, or H\&N cancers.
- First, participants will be accrued in Dose Escalation Part with 4 dose levels to estimate MTD of [212Pb]VMT-Alpha-NET. Once MTD is estimated, the following participants with GI NET, PPGL, SCLC, KC, or H\&N cancers will be accrued in separate cohorts and treated at MTD of [212Pb]VMT-Alpha-NET.
- [212Pb]VMT-Alpha-NET will be given IV every 8 weeks for a total of 4 administrations.
- A subset of participants (Dosimetry Arm 1) will have [203Pb]VMT-Alpha-NET administration followed by whole body gamma scans combined with dosimetry SPECT/ Computed Tomography (CT) scans and collection of blood and urine samples prior each cycle.
- Participants will have timed clinical laboratory evaluations, imaging studies, and research blood, and urine samples while on the study therapy for safety and efficacy evaluations.
- Following completion of treatment, participants will be seen at the NIH Clinical Center approximately 8 weeks after the last study drug administration for an end of treatment (EOT) visit. After EOT, visits will continue every 12 weeks for years 1-3 and every 6 months for years 4-6 or until disease progression. Beyond 6 years (or after disease progression), participants will be contacted annually through any NIH-approved platform to assess for overall survival and health status for 10 years after the end of treatment visit (8 weeks after the last study drug administration).
- Conditions
- Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory Neuroblastoma, Somatostatin Receptor Positive, Small Cell Lung Cancers
- Being tested
- [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE
- Keywords
- 212Pb, Targeted alpha Therapy, Image-Guided Dosimetry, VMT-alpha-NET
- Medical subject headings
- Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory, Pheochromocytoma, Paraganglioma, Kidney Neoplasms, Head and Neck Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
[212Pb]VMT-alpha-NETDrug
[212Pb]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during dose expansion. One cycle is 8 weeks.
[203Pb]VMT-alpha-NETDrug
[203Pb]VMT-alpha-NET will be given IV within 30 days prior to each [212Pb]VMT-alpha-NET infusion.
68Ga-DOTATATEDrug
68Ga-DOTATATE PET/CT whole-body scanning will be done at different intervals to monitor disease.
| Study group | Role | What they receive |
|---|---|---|
| 1/Dosimetry Arm 1 | Experimental | Escalating doses of [212Pb]VMT-alpha-NET, imaging with [203Pb]VMT-alpha-NET Receives: Drug: [212Pb]VMT-alpha-NET; Drug: [203Pb]VMT-alpha-NET; Drug: 68Ga-DOTATATE |
| 2/Arm 2 | Experimental | Escalating doses of [212Pb]VMT-alpha-NET Receives: Drug: [212Pb]VMT-alpha-NET; Drug: 68Ga-DOTATATE |
| 3/Arm 3 | Experimental | [212Pb]VMT-alpha-NET at MTD Receives: Drug: [212Pb]VMT-alpha-NET; Drug: 68Ga-DOTATATE |
What is being measured
The primary outcome is the main question the study is designed to answer.
MTD of [212Pb]VMT-alpha-NET (dose escalation cohort) and safety of [212Pb]VMT-alpha-NET at the MTD (dose expansions cohorts)
The MTD will be presented as a recommended dose to be used in Dose Expansion Part for each disease group being studied.Descriptive tabulations of toxicity will be provided in Dose Expansion Part, along with the agent attribution determination and CTCAE grade for each toxicity event. The data will be presented as an absolute count of the event at a participant level as well as a percentage of total evaluable participants.
Measured: DLTs through 12 weeks after initial 212Pb]VMT-alpha-NET administration (dose escalation) and all toxicities from day 1 up through 6 years (dose expansion).
Secondary outcomes (6)
Dosimetry properties of [212Pb]VMT-alpha-NET via SPECT/CT, using [203Pb]VMT-alpha-NET as a surrogate with and without the administration of amino acids (Dosimetry Arm 1 only)
Biodistribution and dosimetry data will be represented in a tabular format which indicates the percentage of the injected dose calculated to be in each of the major organs using gamma scan results. Radiation dose calculations will be performed using OLINDA/EXM software. Absorbed doses in organs and the whole body will be determined using the appropriate adult phantom (e.g., adult male, adult female). Tumor lesion absorbed doses will be determined using the sphere model in OLINDA.
Measured: After each SPECT/CT and gamma planar imaging and after every [203Pb]VMT-alpha-NET infusion (in Dosimetry Arm 1 only)
PK properties of [212Pb]VMT-alpha-NET via blood and urine sampling
PK data will be represented as a scatter plot graphing time vs. the amount of radioactivity found in blood and urine samples.
Measured: After every infusion of [212Pb]VMT-alpha-NET
Overall Survival
Kaplan-Meier curves of OS, will be constructed. Median OS will be reported with 95% confidence intervals.
Measured: Baseline until progression or 6 years after the end of treatment visit
Safety of [203Pb]VMT-alpha-NET (dose escalation cohort) and [212Pb]VMT-alpha-NET
Descriptive tabulations of toxicity will be provided, along with the agent attribution determination and CTCAE grade for each toxicity event. The data will be presented as an absolute count of the event at a participant level as well as a percentage of total evaluable participants.
Measured: Study duration
Progression Free Survival
PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Kaplan-Meier curves of PFS will be constructed. Median PFS and OS will be reported with 95% confidence intervals.
Measured: Baseline until progression or 6 years after the end of treatment visit
Overall Response Rate
The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The overall response rate will be presented as a percentage along with 95% confidence intervals. Only evaluable participants will be included.
Measured: Baseline, weeks 12 and 32 during treatment, every 12 weeks after that until progression or 6 years after the end of treatment visit.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jun 2024
- Study start19 Aug 2025
- Primary completion1 Jan 2029 (estimated)
- Study completion1 Jan 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sinonasal Neuroendocrine CarcinomaStudies of the same condition, open and under way.
- More trials run by National Cancer Institute (NCI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Frank I Lin, M.D., Principal investigator, National Cancer Institute (NCI)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06479811
- Sponsor's protocol ID
- 10001709
- Other IDs
- 001709-C
- Status last verified
- 2 Oct 2026
- First submitted
- 27 Jun 2024
- Last updated
- 6 Oct 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: All IPD recorded in the medical record will be shared with intramural investigators upon request. This study will comply with the NIH Data Management and Sharing (DMS) Policy, which applies to all new and ongoing NIH-funded research in the IRP, as of January 25, 2023, that is associated with a ZIA, with a clinical protocol that undergoes scientific review.